The C1RL Knockout A-549 Polyclonal Cells consist of a CRISPR/Cas9-mediated polyclonal knockout population targeting the C1RL gene in the A-549 human lung adenocarcinoma cell line. This pooled format represents a heterogeneous collection of cells carrying disruptive edits at the C1RL locus, providing a robust loss-of-function tool for studying complement-related pathways in an epithelial cancer context. The polyclonal nature ensures that phenotypic observations account for clonal variability and avoid artifact associated with single clone isolation.
A-549 cells were originally derived from a 58-year-old male patient with lung carcinoma and exhibit adherent epithelial morphology. As a widely utilized model of human lung adenocarcinoma, this cell line recapitulates key features of non-small cell lung cancer, including oncogenic mutations and drug sensitivity profiles. Its well-characterized transcriptional landscape and tractability for genetic manipulation make it a standard platform for cancer biology, signal transduction, and pharmacological testing, particularly in the context of tumor-immune interactions.
C1RL encodes a serine protease predicted to function in the classical complement pathway, activated by C1q in association with immune complexes or pattern recognition molecules including mannan-binding lectin and ficolins. Together with C1s, C1RL cleaves complement C4 and C2 to form the C3 convertase (C4b2a), which then processes C3 into C3a and C3b, ultimately driving membrane attack complex (MAC) assembly and pro-inflammatory anaphylatoxin release. Regulatory control is exerted by SERPING1 (C1 inhibitor). Outside the complement cascade, C1RL may participate in extracellular matrix remodeling through non-canonical proteolytic events, potentially impacting tumor cell adhesion and migration.
Disruption of C1RL in A-549 cells is expected to impair classical complement cascade initiation, leading to diminished C4 and C2 cleavage and attenuated downstream activation of C3 convertase and MAC assembly. This blockade likely alters the tumor microenvironment by reducing complement-mediated inflammation and opsonization, which could modulate immune surveillance and tumor progression. Given that complement components are increasingly recognized as participants in tumor immune evasion and stromal remodeling, this knockout model provides a valuable tool to dissect how tumor-intrinsic complement activity influences lung adenocarcinoma cell phenotypes, including apoptosis resistance, migratory capacity, and response to chemotherapeutic agents.
Researchers can employ the C1RL Knockout A-549 Polyclonal Cells in diverse experimental contexts, including profiling complement activation via C4/C2 cleavage assays, assessing cell viability and apoptotic responses, and performing migration and invasion studies to evaluate ECM interactions. Transcriptomic analysis by RNA-seq, immunofluorescence for MAC deposition, and cytokine profiling enable detailed characterization of downstream signaling consequences. The cells are also suitable for co-immunoprecipitation to map interaction networks and for screening complement-targeted inhibitors in oncological settings. For inquiries regarding batch availability, technical specifications, or collaborative use cases, please contact Ascent Research.
